Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies - PubMed
5 hours ago
- #xenograft models
- #breast cancer
- #neoadjuvant therapy
- Patient-derived xenograft (MIND-PDX) models were developed for preclinical evaluation of neoadjuvant therapies in primary breast cancer.
- A cohort of 60 MIND-PDX models representing all subtypes of invasive breast cancer (IBC) was created, along with seven matched PDX-derived organoids.
- The study demonstrated that adding a PARP inhibitor did not benefit neoadjuvant treatment for triple-negative IBC.
- For estrogen receptor-positive IBC, combining a CDK4/6 inhibitor with fulvestrant improved neoadjuvant treatment response.
- The IBC-MIND cohort serves as a valuable resource for studying breast cancer biology and developing neoadjuvant treatments.